ESTRO 2024 - Abstract Book

S2538

Clinical - Urology

ESTRO 2024

Keywords: second cancer, radiotherapy, prostate cancer

References:

1) Evers J, Kerkmeijer LGW, van den Bergh RCN, van der Sangen MJC, Hulshof MCCM, Bloemers MCWM, et al. Trends and variation in the use of radiotherapy in non-metastatic prostate cancer: A 12-year nationwide overview from the Netherlands. Radiother Oncol. 2022;177:134-42.

2) Bommeé J, Walters BH, Willemsen M. Smoking in the Netherlands: Key Statistics for 2021. Trimbos-instituut: Utrecht, The Netherlands. 2022.

2502

Digital Poster

Can we predict extraprostatic/metastatic disease on PSMA PET-CT based on PSA, MRI and Gleason grade?

Bhanu Vashistha 1 , Kurian J Puthur 1 , Moses Arunsingh 1 , Jayanta Das 2 , Soumen Ray 2 , Indranil Mallick 1

1 Tata Medical Center, Radiation Oncology, Kolkata, India. 2 Tata Medical Center, Nuclear Medicine, Kolkata, India

Purpose/Objective:

Prostate Specific Antigen(PSA) threshold for imaging and the modality of imaging at biochemical progression after curative intent radiation therapy is currently not standardized. With the availability of novel imaging modalities like Prostate specific membrane antigen-Positron Emission Tomography(PSMA-PET), it may be possible to detect clinically actionable recurrence early in the natural history of disease progression. We conducted an audit of PSMA PET based evaluation of rising PSA levels after curative intent treatment to audit disease detection, especially metastatic disease, and assess whether assessment prior to the Phoenix criteria yields meaningful results.

Material/Methods:

One hundred and ninety six (196) patients with prostate cancer, who underwent a PSMA PET scan for staging of prostate cancer in the period September 2017 to May 2023 were retrospectively analyzed. Data was extracted from electronic medical records. The incidence of detection of extraprostatic disease or distant metastases was described. Logistic regression was used to determine if the PSA at diagnosis, Gleason grade group and multiparametric MRI based T stage could predict for PSMA-PET based detection of any extraprostatic disease